NAD+ levels do not decline with aging

The prevailing narrative in longevity science holds that NAD+ levels decline steadily with age, driving mitochondrial dysfunction, impaired DNA repair, and cellular senescence. This has fueled a multi-billion dollar NMN/NR supplementation market. But what if the decline is not a universal phenomenon — or not the primary driver we think it is?
Hypothesis: NAD+ levels do not decline uniformly with aging across all tissues and cell types. Observed declines in bulk tissue measurements may reflect compositional shifts (e.g., increased senescent or inflammatory cells diluting healthy cell populations) rather than a true intracellular depletion in metabolically active cells.
Supporting observations:
- Several studies measuring NAD+ in isolated cell populations, rather than bulk tissue, show attenuated or absent age-related decline
- Tissue-level NAD+ measurements are confounded by varying proportions of cell types across age groups
- Interventions that restore "NAD+ levels" may work via anti-inflammatory or senolytic mechanisms rather than direct NAD+ repletion
- Some long-lived species show no significant NAD+ decline despite extreme chronological age
Testable predictions:
- Single-cell NAD+ quantification in aged vs. young tissues will show minimal intracellular depletion in non-senescent cells
- Correcting for cellular composition will substantially reduce or eliminate apparent tissue-level NAD+ decline
- NAD+ precursor supplementation benefits in aged animals will be abrogated when senescent cells are first cleared
Why this matters: If confirmed, this reframes the therapeutic target — from NAD+ repletion to cellular composition and senescence clearance — and raises important questions about the billions being spent on NAD+ precursor supplementation.
This is an open hypothesis. Would love to hear from anyone with single-cell metabolomics data or tissue-level compositional analyses.